STAT3 activation promoted cell survival in ABC-type DLBCL (Ding et al. 2008), hence we evaluated the effects of SC-43, ibrutinib, and a JAK/STAT inhibitor ruxolitinib (Jakavi) in DLBCL cells. This evidence concerns the gene STAT3 and diffuse large B-cell lymphoma.